Measuring the blockade of malaria transmission – An analysis of the Standard Membrane Feeding Assay
2012/09/27 by Thomas S. Churcher, Andrew M. Blagborough, Michael J. Delves +8 · 26 citations
Medicine · Agricultural and Biological Sciences · #Malaria Research and Control #Mosquito-borne diseases and control #Insect Pest Control Strategies
paper · doi:10.1016/j.ijpara.2012.09.002
Abstract
The standard membrane feeding assay (SMFA) is currently considered to be the 'gold standard' for assessing the effectiveness of malaria transmission blocking interventions (TBIs) in vivo. The operation and analysis of SMFAs has varied between laboratories: field scientists often measure TBI efficacy as a reduction in the prevalence of infected mosquitoes whilst laboratory scientists are more likely to quote efficacy as a change in the number of oocysts within the mosquito. These metrics give outputs that differ widely, resulting in a need for greater understanding of how the SMFA informs TBI assessment. Using data from 536 different assays (conducted on Plasmodium falciparum and Plasmodium berghei, in either Anopheles gambiae or Anopheles stephensi) it is shown that the relationship between these metrics is complex, yet predictable. Results demonstrate that the distribution of oocysts between mosquitoes is highly aggregated, making efficacy estimates based on reductions in intensity highly uncertain. Analysis of 30 SMFAs carried out on the same TBI confirms that the observed reduction in prevalence depends upon the parasite exposure (as measured by oocyst intensity in the control group), with assays which have lower exposure appearing more effective. By contrast, if efficacy is estimated as a reduction in oocyst intensity, then this candidate demonstrated constant efficacy, irrespective of the exposure level. To report transmission-blockade efficacy accurately, the results of SMFAs should give both the prevalence and intensity of oocysts in both the control and intervention group. Candidates should be assessed against a range of parasite exposures to allow laboratory results to be extrapolated to different field situations. Currently, many studies assessing TBIs are underpowered and uncertainties in efficacy estimates rarely reported. Statistical techniques that account for oocyst over-dispersion can reduce the number of mosquitoes that need to be dissected and allow TBI candidates from different laboratories to be accurately compared.
Cited by
- Antibodies to a Single, Conserved Epitope in Anopheles APN1 Inhibit Universal Transmission of Plasmodium falciparum and Plasmodium vivax Malaria
- Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. [europepmc]
- Antimalarial drug discovery - approaches and progress towards new medicines. [europepmc]
- The relevance and applicability of oocyst prevalence as a read-out for mosquito feeding assays. [europepmc]
- Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. [europepmc]
- Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. [europepmc]
- A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. [europepmc]
- Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. [europepmc]
- Antibiotics in ingested human blood affect the mosquito microbiota and capacity to transmit malaria. [europepmc]
- The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope. [europepmc]
- Malaria vaccines and human immune responses. [europepmc]
- Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay. [europepmc]
- An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines. [europepmc]
- Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. [europepmc]
- Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. [europepmc]
- Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity. [europepmc]
- Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity. [europepmc]
- Plasmodial Kinase Inhibitors: License to Cure? [europepmc]
- Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. [europepmc]
- Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults. [europepmc]
- Pf s230 and Pf s48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum . [europepmc]
- When Is a Plasmodium-Infected Mosquito an Infectious Mosquito? [europepmc]
- Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. [europepmc]
- Transmission-Blocking Vaccines: Harnessing Herd Immunity for Malaria Elimination. [europepmc]
- Plasmodium oocysts respond with dormancy to crowding and nutritional stress. [europepmc]
- Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. [europepmc]
Related